MedTrace Logo

Paricalcitol Injection Phase II Trial

NCT00646932 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2008-03-31

No results posted yet for this study

Summary

The PK and tolerability of paricalcitol after repeated intravenous administration for 2 weeks (total 6 doses at every HD session) are studied in subjects with 2°HPT who are receiving HD 3 times a week for stable chronic renal failure.

Conditions

Interventions

DRUG

paricalcitol

paricalcitol 0.04 mcg/kg three times a week

DRUG

paricalcitol

paricalcitol 0.08 mcg/kg three times a week

DRUG

paricalcitol

paricalcitol 0.16 mcg/kg three times a week

DRUG

paricalcitol

paricalcitol 0.24 mcg/kg three times a week

Sponsors & Collaborators

Principal Investigators

  • Hideaki Harada · Abbott

Study Design

Allocation
NON_RANDOMIZED
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
74 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-11-30
Primary Completion
2007-02-28

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00646932 on ClinicalTrials.gov